Korro Bio Inc (NASDAQ: KRRO) is a clinical-stage biopharmaceutical company developing RNA editing therapies that make precise single-base edits to target disease-causing proteins. The company generates no product revenue. Its primary disclosed funding arrangement is a Research Collaboration and License Agreement with Novo Nordisk A/S, signed September 13, 2024, with a first amendment filed November 12, 2025, alongside equity offerings and potential future licensing deals. Korro Bio's lead scientific approach targets TDP-43, an RNA/DNA-binding protein whose aggregation is implicated in more than 90% of ALS cases and approximately 45% of frontotemporal dementia cases, per the FY2025 10-K filed March 12, 2026. The company has no approved products and no committed external source of funds, financing operations through equity offerings, debt, and collaboration agreements. Ram Aiyar serves as President and Chief Executive Officer, with Oliver Dolan as Senior Vice President of Finance and Principal Accounting Officer, as disclosed in the FY2025 10-K.

Revenue model

Korro Bio has no product revenue as of the FY2025 10-K (filed March 12, 2026). The company finances operations through equity offerings, debt financings, and collaboration and licensing arrangements, including a Research Collaboration and License Agreement with Novo Nordisk A/S executed September 13, 2024.

Products and services

Korro Bio's pipeline centers on RNA editing therapies that introduce single amino acid changes to target proteins. The lead program targets TARDBP, the gene encoding TDP-43, aiming to produce a non-aggregating TDP-43 protein variant as a potential treatment for ALS and frontotemporal dementia. All programs are in preclinical or early development stages as of the FY2025 10-K.

Customers and end markets

The end markets are patients with ALS and frontotemporal dementia. More than 90% of ALS patients and approximately 45% of FTD patients have TDP-43 aggregations in neurons, per the FY2025 10-K. Less than 10% of ALS cases are familial; TARDBP mutations account for approximately 4% of familial ALS cases. There are no commercial customers disclosed.

Value-chain role

Korro Bio is a drug discovery and development company operating entirely upstream of commercialization. It conducts preclinical research internally, relies on third-party manufacturers for any future clinical supply, and has licensed rights to Novo Nordisk A/S under a collaboration agreement. No products have reached regulatory approval.

Geographic exposure

Korro Bio is a U.S.-incorporated company subject to FDA regulatory oversight for its drug development activities. The FY2025 10-K references GDPR compliance obligations for the EEA and UK, indicating data handling exposure in those regions, but no commercial geographic revenue mix is disclosed.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: X4 Pharmaceuticals Inc ZEO ScientifiX Inc Bolt Biotherapeutics Inc Cardiff Oncology Inc Curis Inc Equillium Inc Synlogic Inc Pyxis Oncology Inc SQZ Biotechnologies Co